Indietro

Selezionare la regione

Azienda

Richiedi un consulto sulle cellule staminali

Per saperne di più

I nostri
trapianti

Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:

Immagine
Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:
Nr. Fonte Tipo di fonte Diagnosi Settore medico Anno di applicazione Terapia Paese Età del destinatario
501 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 56
502 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 69
503 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Portugal 32
504 Apheresis Autologous Lymphoma Hematology 2026 Standard Therapy Portugal 64
505 Apheresis Autologous Lymphoma Hematology 2026 Standard Therapy Portugal 64
506 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 42
507 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 65
508 Apheresis Allogeneic Chronic myelomonocytic leukemia Hematology 2026 Standard Therapy Germany 73
509 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 63
510 Apheresis Allogeneic Thalassemia Major Hematology 2026 Standard Therapy Italy 6
511 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 63
512 Apheresis Allogeneic Hemophagocytic Lymphohistiocytosis Hematology 2026 Standard Therapy India 3
513 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Bulgaria 32
514 Apheresis Allogeneic Mixed-Phenotype Acute Leukemia Hematology 2026 Standard Therapy Poland 40
515 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 64
516 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Ukraine 58
517 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 62
518 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 45
519 Apheresis Allogeneic T-cell non-Hodgkin Lymphoma (Mycosis Fungoides) Hematology 2026 Standard Therapy Portugal 43
520 Apheresis Allogeneic Plasma Cell Leukemia Hematology 2026 Standard Therapy Germany 62
521 Apheresis Allogeneic Hodgkin’s Disease Hematology 2026 Standard Therapy Italy 34
522 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy France 20
523 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 40
524 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 51
525 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 58
526 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Ukraine 45
527 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ukraine 41
528 Apheresis Allogeneic Hodgkin's Disease Hematology 2026 Standard Therapy Poland 44
529 Apheresis Allogeneic Multiple Myeloma Hematology 2026 Standard Therapy USA 47
530 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Colombia 57
531 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Australia 72
532 Apheresis Allogeneic EBV-positive nodal T- and NK-cell lymphoma Hematology 2026 Standard Therapy Poland 68
533 Apheresis Allogeneic Acute Myeloid Leukemia, Myelodysplasia-Related Hematology 2026 Standard Therapy Russia Federation 48
534 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Finland 69
535 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 67
536 Apheresis Allogeneic Large Cell Anaplastic Lyphoma ALK Hematology 2026 Standard Therapy Serbia 13
537 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 74
538 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Lithuania 64
539 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 67
540 Apheresis Allogeneic Acute Undifferentiated Leukemia Hematology 2026 Standard Therapy USA 16
541 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Czechia 53
542 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
543 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy India 18
544 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 50
545 Apheresis Allogeneic Chronic myelomonocytic leukemia Hematology 2026 Standard Therapy Lithuania 66
546 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 51
547 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 41
548 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 72
549 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 70
550 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 61
551 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Lithuania 62
552 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 62
553 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Spain 61
554 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 58
555 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy India 2
556 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 21
557 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 63
558 Apheresis Autologous Diffuse Large B-cell Lymphoma Hematology 2026 Standard Therapy Germany 71
559 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 61
560 Apheresis Autologous Mantle Cell Lymphoma Hematology 2026 Standard Therapy Germany 65
561 Apheresis Autologous T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 64
562 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 70
563 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 59
564 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 66
565 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
566 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 53
567 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2026 Standard Therapy France 26
568 Apheresis Allogeneic Inherited Metabolic Disorder Hematology 2026 Standard Therapy France 50
569 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 70
570 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 70
571 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Argentina 30
572 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 74
573 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 61
574 Apheresis Allogeneic Hyper IgE Syndrome Hematology 2026 Standard Therapy Australia 11
575 Apheresis Allogeneic AML FLT3+ Hematology 2026 Standard Therapy Croatia 61
576 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 61
577 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 58
578 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Iran 3
579 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 59
580 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 58
581 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 10
582 Apheresis Allogeneic Lymphoma – Peripheral T cell Hematology 2026 Standard Therapy United Kingdom 53
583 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 48
584 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Spain 13
585 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Italy 58
586 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 69
587 Apheresis Allogeneic Peripheral T Cell Lymphoma With Haemophagocytic Lymphohistiocytosis Hematology 2026 Standard Therapy United Kingdom 52
588 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 62
589 Apheresis Allogeneic T-Cell Prolymphocytic Leukemia Hematology 2026 Standard Therapy Italy 72
590 Apheresis Allogeneic Myelodysplastic Disorder Hematology 2026 Standard Therapy Russian Federation 51
591 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 64
592 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 62
593 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 49
594 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 75
595 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
596 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 58
597 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 52
598 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 69
599 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 20
600 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 65